ClinicalTrials.gg
RecruitingNCT07435610Updated Jun 5, 2026

Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction

An interventional study of Active Therapeutic acupuncture intervention and Sham therapeutic acupuncture treatment in Disorders of Gut-brain Interaction, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Children's Hospital of Orange County · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Study summary

Disorders of Gut-Brain Interactions (DGBIs) significantly impact children globally, leading to reduced quality of life and increased healthcare utilization. Despite their prevalence, effective treatments for pediatric DGBIs remain limited. Acupuncture, though commonly used in clinical practice and supported by adult data, lacks robust empirical evidence in pediatric populations. This study addresses this critical gap.

The primary objective is to assess the efficacy of acupuncture in reducing symptom severity in pediatric patients with DGBIs. Key secondary objectives include evaluating improvements in quality of life, functional disability, and mental health outcomes.

This is a parallel-group, randomized, placebo sham-controlled, participant-blind clinical trial. The study is being conducted in an outpatient pediatric referral center. A total of 96 participants, aged 8-17 years, meeting eligibility criteria for DGBIs will be enrolled. Participants must be medically stable and meet protocol-defined inclusion/exclusion criteria.

Participants will be randomly assigned to receive either acupuncture or sham acupuncture, alongside standard care. Treatments will occur over a predefined protocol period. Data will be collected at baseline, during treatment, and at specified post-treatment intervals. The primary outcomes will evaluate changes in pain intensity and frequency. Secondary outcomes will include assessments of pain resolution, quality of life, functional disability, and mental health. Statistical analyses will employ rigorous methodologies to ensure reliability and validity of findings.

02

Conditions studied

  • Disorders of Gut-brain Interaction
03

In context

Lead sponsor

Children's Hospital of Orange County is the lead sponsor of 19 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 8-17 years
  2. Diagnosis of FAP-NOS, IBS, or abdominal migraine (Rome IV criteria; partial criteria permitted)
  3. Stable use (≥8 weeks) of antidepressant and/or ADHD medications, if applicable
  4. Functional constipation, if present, controlled on maintenance therapy
  5. Ability of participant and caregiver to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with IB-Stim, acupuncture, or other auricular/percutaneous nerve field stimulation modalities.
  2. Diagnosis of functional dyspepsia.
  3. Untreated constipation at screening.
  4. Use of ketamine, opioids, antibiotics, or probiotics within 2 weeks prior to treatment initiation
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Active

    The active treatment group will receive standardized acupuncture based on a protocol for functional abdominal pain, using seven acupuncture points: ST36 (Zusanli), LV3 (Taichong), REN12 (Zhongwan), PC6 (Neiguan), SP4 (Gongsun), EX-HN (Sishencong), and DU24 (Shenting) using sterile, single-use Seirin needles. Sessions will occur once weekly for eight weeks, each lasting 40 minutes.

    Other: Active Therapeutic acupuncture intervention

  • Sham comparator
    Control/Sham

    The control group will receive Park Sham Acupuncture Devices at the same scalp points, designed to mimic the sensation of acupuncture without actual needle insertion. Both groups will continue receiving standard care throughout the study.

    Other: Sham therapeutic acupuncture treatment

Interventions

  • OtherActive Therapeutic acupuncture intervention

    P-GAP is a prospective, randomized, placebo (sham)-controlled, participant- and assessor-blinded superiority trial. The trial evaluates the efficacy and safety of acupuncture in pediatric patients with DGBIs. Participants will be randomly assigned to receive either standardized acupuncture or sham acupuncture over an 8-week treatment period, followed by a post-treatment evaluation. The study includes a screening and run-in phase, a treatment phase, and a follow-up phase.

  • OtherSham therapeutic acupuncture treatment

    Control/sham group participants will receive sham acupuncture using sterile, single-use Park Sham Acupuncture Devices at identical scalp points. This mimics the sensation of acupuncture without needle insertion to maintain participant blinding.

06

What researchers measure

Primary outcomes

  1. Adequate Pain Relief:

    The primary outcome is the proportion of participants achieving adequate pain relief, defined as a ≥30% reduction from baseline in mean abdominal pain severity on the 11-point Numerical Rating Scale from baseline to follow-up at Weeks 12-14. This threshold reflects the Rome Foundation's definition of clinically meaningful improvement in pediatric functional abdominal pain disorders.

    Time frame: Baseline to Weeks 12-14

Secondary outcomes

  1. Pain Severity

    Pain intensity will be measured using the 11-point Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain). Participants will record daily NRS scores during the baseline run-in period and at Weeks 4-5, 8-9, and 12-14. For each timepoint, pain severity will be defined as the means of daily scores recorded over the final 7 days. Change in mean pain severity will be evaluated from baseline to follow-up at Weeks 12-14.

    Time frame: Baseline to Week 12-14

  2. Pain Frequency

    Participants will record the number of pain episodes using daily symptom diaries. Outcomes will be defined as the mean number of episodes recorded over the final 7 days of each assessment period, including baseline and follow-up assessment at Week 12-14.

    Time frame: Baseline to Week 12-14.

  3. Rome IV diagnostic classification

    DGBI status will be assessed using Rome IV questionnaires at baseline, Week 4, Week 8, and Week 12-14. Changes in whether participants meet Rome IV criteria for specific DGBIs will be evaluated over time.

    Time frame: Baseline to Week 12-14

  4. Health-Related Quality of Life

    Health-related quality of life will be measured using the Pediatric Quality of Life Inventory™ (PedsQL™) Gastrointestinal Symptoms Module at baseline, Week 4, Week 8, and Week 12-14

    Time frame: Baseline to Week 12-14

  5. Psychological Well-Being

    Anxiety and depressive symptoms will be measured using the PROMIS Pediatric Anxiety and Depression Scales at baseline, Week 4, Week 8, and Week 12-14.

    Time frame: Baseline to Week 12-14.

  6. Safety and Serious Adverse Events (SAEs)

    Safety will be assessed based on the incidence, severity, and relatedness of adverse events, classified using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Serious adverse events will be reviewed and reported in accordance with institutional requirements.

    Time frame: Baseline to Week 12-14

07

Study locations

1 of 1 sites recruiting
  • CHOC Center for Children's Health Building: Joe C. Wen & Family Center for Advanced Care (CAC)
    Irvine, California 92612, United States
    Recruiting
    • Heidi Joyce, BS · Contactheidi.joyce@choc.org · 714-509-8765
    • Ashish Chogle, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the final publication will be made available upon reasonable request, where legally and ethically permissible, after completion of the study and publication of the primary results. Requests will be reviewed by the study investigators and may require approval of a proposal and execution of a data use agreement.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data and supporting materials will be available after completion of the study and publication of the primary results.

Access criteria: Access will be provided to qualified researchers upon reasonable request, where legally and ethically permissible. Requests will be reviewed by the study investigators and may require approval of a proposal and execution of a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Feb 27, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2028
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07435610
Lead sponsor
Children's Hospital of Orange County
Responsible party
Ashish Chogle (Principal Investigator, Children's Hospital of Orange County) — Principal investigator
First posted
Feb 27, 2026
Start date
Jan 8, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jun 5, 2026

Study contacts

Pari Mokhtari
Contact
pmokhtari@choc.org
(714)509-4264
Heidi Joyce
Contact
Heidi.joyce@choc.org
(714)509-8765

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion